三大激素系统靶向分析识别与非酒精性脂肪性肝病存在及严重程度相关的分子
该研究通过两个研究比较了前胰高血糖素衍生激素、卵泡抑素-激活素及IGF轴在NAFLD患者与对照中的循环水平及肝脏基因表达,发现早期NAFLD患者空腹MPGF升高且口服葡萄糖耐量试验中glicentin增量降低,FSTL3在NASH及严重炎症中升高,IGF-1/完整IGFBP-3比值在肝纤维化患者中降低,提示这些分子可能作为诊断标志物或治疗靶点。
要点
- 早期NAFLD患者空腹MPGF升高且OGTT中glicentin增量降低。
- FSTL3水平在NASH及严重小叶和门管区炎症中更高。
- IGF-1/完整IGFBP-3比值在肝纤维化患者中降低。
核心结论
- MPGF和glicentin可能参与NAFLD早期阶段,而FSTL3和IGF-1/完整IGFBP3分别与NASH进展和肝纤维化相关,提示其作为诊断标志物或治疗靶点的潜力。
研究设计与样本
- 研究1比较18例早期NAFLD患者与14例对照的循环激素水平;研究2比较31例活检证实的NAFLD患者(15例单纯性脂肪变,16例NASH)与50例对照(24例瘦型,26例肥胖)的循环激素水平;另在22例受试者(12例对照,5例NASH,5例NASH相关肝硬化)中评估肝脏基因表达。
主要发现
- 早期NAFLD患者空腹MPGF高于对照,且口服葡萄糖耐量试验中glicentin增量低于对照。
- NASH患者FSTL3水平高于单纯性脂肪变,且在NAFLD患者中,小叶和门管区炎症更严重者FSTL3水平更高。
- 肝纤维化患者IGF-1/完整IGFBP-3比值降低。
- NASH患者肝脏中卵泡抑素、激活素A、激活素B和IGF-1受体基因表达升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate circulating levels and liver gene expression of 3 hormonal pathways associated with obesity, insulin resistance, and inflammation to identify leads towards potential diagnostic markers and therapeutic targets in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We compared circulating levels of (1) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), (2) follistatins-activins (follistatin-like [FSTL]3, activin B), (3) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy-associated plasma protein [PAPP]-A) in 2 studies: (1) 18 individuals with early stage NAFLD versus 14 controls (study 1; early NAFLD study) and in (2) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs 50 controls (24 lean and 26 obese) (study 2). Liver gene expression was assessed in 22 subjects (12 controls, 5 NASH, 5 NASH-related cirrhosis). RESULTS: Patients in early stages of NAFLD demonstrate higher fasting MPGF and lower incremental increase of glicentin during oral glucose tolerance test than controls. In more advanced stages, FSTL3 levels are higher in NASH than simple steatosis and, within NAFLD patients, in those with more severe lobular and portal inflammation. The IGF-1/intact IGFBP-3 ratio is lower in patients with liver fibrosis. Genes encoding follistatin, activin A, activin B, and the IGF-1 receptor are higher in NASH. CONCLUSION: MPGF and glicentin may be involved in early stages of NAFLD, whereas FSTL3 and IGF-1/intact IGFBP3 in the progression to NASH and liver fibrosis respectively, suggesting potential as diagnostic markers or therapeutic targets.
引用
- Polyzos SA, Perakakis N, Boutari C, et al. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. J Clin Endocrinol Metab. 2020. PMID: 31690932. doi:10.1210/clinem/dgz172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。